See the DrugPatentWatch profile for vascepa

Vascepa, a prescription medication, contains the active ingredient icosapent ethyl. It is used to lower triglyceride levels in adult patients with severe (200-499 mg/dL) or very high (≥500 mg/dL) levels of triglycerides [1]. While it is not specifically marketed as a treatment for pre-existing conditions, it can be beneficial for patients with certain health issues.

For patients with pre-existing cardiovascular disease, Vascepa has demonstrated positive effects. In the REDUCE-IT trial, a large-scale study involving over 8,000 patients, Vascepa reduced the risk of major adverse cardiovascular events by 25% in patients with established cardiovascular disease or diabetes and additional risk factors [2].

Vascepa may also provide benefits for patients with high-risk diabetes. In the REDUCE-IT trial, Vascepa reduced the risk of ischemic events, including cardiovascular death, in patients with diabetes and multiple risk factors [2].

It is important to note that Vascepa is not a cure for pre-existing conditions, but it can help manage certain aspects of these conditions, such as lowering triglyceride levels and reducing the risk of cardiovascular events.

In summary, Vascepa can aid patients with pre-existing conditions by lowering triglyceride levels and reducing the risk of cardiovascular events in patients with established cardiovascular disease or diabetes and additional risk factors [2].

Sources:
[1] "Vascepa." Drugs.com, www.drugs.com/vascepa.html.
[2] Bhatt, Deepak L., et al. "Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia." The New England Journal of Medicine, vol. 379, no. 15, 2018, pp. 1583-1592., doi:10.1056/nejmoa1807001.
[3] "Icosapent Ethyl." DrugPatentWatch, drugpatentwatch.com/drugs/icosapent-ethyl.